Literature DB >> 11344239

Tumor necrosis factor-alpha expression in human uterine leiomyoma and its down-regulation by progesterone.

O Kurachi1, H Matsuo, T Samoto, T Maruo.   

Abstract

Although tumor necrosis factor-alpha (TNFalpha) has been shown mainly to inhibit proliferation and induce apoptosis in a variety of cells, no information is available regarding whether human leiomyoma cells express TNFalpha. In the present study, we examined the expression of TNFalpha in leiomyomas, in comparison with that in the adjacent normal myometrium, using immunohistochemical staining and Western immunoblot analysis with a polyclonal antibody to human TNFalpha. Furthermore, we investigated the effect of sex steroid hormones on TNFalpha expression in leiomyoma cells cultured under serum-free, phenol red-free conditions. Immunohistochemical staining showed that TNFalpha expression in leiomyoma cells was higher than that in the adjacent normal myometrial cells, being more abundant in the proliferative phase than in the secretory, progesterone (P4)-dominated, phase of the menstrual cycle. TNFalpha expression in leiomyoma cells in pregnant uterus was scarce. Western immunoblot analyses of leiomyoma and normal myometrial tissue extracts revealed that TNFalpha, with a molecular mass of 17.3 kDa, was abundantly present in leiomyoma tissue extracts, relative to normal myometrial tissue extracts, and that TNFalpha expression in leiomyoma cells was most abundant in the proliferative phase of the menstrual cycle, less abundant in the secretory phase, and least abundant in pregnant uterus; whereas no such changes in TNFalpha expression were noted in the normal myometrium. In monolayer cultures of uterine leiomyoma cells under serum-free conditions, addition of P4 (3.18 x 10(-7) mol/L) resulted in a decrease in TNFalpha expression in the cells, relative to that in control cultures, whereas treatment with 17beta-estradiol (3.67 x 10(-8) mol/L) did not affect the TNFalpha expression in the cells. The concentrations of sex steroids used were within the physiological tissue concentrations noted in leiomyoma and myometrium. The present results suggest that the abundant expression of TNFalpha may be a molecular basis characteristic of leiomyomas in the human uterus and that P4 may play a vital role in down-regulating the expression of TNFalpha in human uterine leiomyoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344239     DOI: 10.1210/jcem.86.5.7469

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Role of microRNA-21 and programmed cell death 4 in the pathogenesis of human uterine leiomyomas.

Authors:  J Browning Fitzgerald; Vargheese Chennathukuzhi; Faezeh Koohestani; Romana A Nowak; Lane K Christenson
Journal:  Fertil Steril       Date:  2012-06-22       Impact factor: 7.329

2.  Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations.

Authors:  James H Segars; Estella C Parrott; Joan D Nagel; Xiaoxiao Catherine Guo; Xiaohua Gao; Linda S Birnbaum; Vivian W Pinn; Darlene Dixon
Journal:  Hum Reprod Update       Date:  2014-01-08       Impact factor: 15.610

Review 3.  Progesterone receptor action in leiomyoma and endometrial cancer.

Authors:  J Julie Kim; Elizabeth C Sefton; Serdar E Bulun
Journal:  Prog Mol Biol Transl Sci       Date:  2009-10-07       Impact factor: 3.622

4.  Non-hormonal mediators of uterine fibroid growth.

Authors:  Esra Cetin; Ayman Al-Hendy; Michał Ciebiera
Journal:  Curr Opin Obstet Gynecol       Date:  2020-10       Impact factor: 1.927

Review 5.  Leiomyomata uteri: hormonal and molecular determinants of growth.

Authors:  Richard Enrique Blake
Journal:  J Natl Med Assoc       Date:  2007-10       Impact factor: 1.798

Review 6.  Use of dietary phytochemicals to target inflammation, fibrosis, proliferation, and angiogenesis in uterine tissues: promising options for prevention and treatment of uterine fibroids?

Authors:  Md Soriful Islam; Most Mauluda Akhtar; Andrea Ciavattini; Stefano Raffaele Giannubilo; Olga Protic; Milijana Janjusevic; Antonio Domenico Procopio; James H Segars; Mario Castellucci; Pasquapina Ciarmela
Journal:  Mol Nutr Food Res       Date:  2014-06-30       Impact factor: 5.914

Review 7.  Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.

Authors:  Md Soriful Islam; Sadia Afrin; Sara Isabel Jones; James Segars
Journal:  Endocr Rev       Date:  2020-10-01       Impact factor: 19.871

Review 8.  Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies†.

Authors:  Abdelrahman AlAshqar; Lauren Reschke; Gregory W Kirschen; Mostafa A Borahay
Journal:  Biol Reprod       Date:  2021-07-02       Impact factor: 4.285

Review 9.  Macrophages and Immune Responses in Uterine Fibroids.

Authors:  Alessandro Zannotti; Stefania Greco; Pamela Pellegrino; Federica Giantomassi; Giovanni Delli Carpini; Gaia Goteri; Andrea Ciavattini; Pasquapina Ciarmela
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

10.  Progesterone prevents traumatic brain injury-induced intestinal nuclear factor kappa B activation and proinflammatory cytokines expression in male rats.

Authors:  Gang Chen; Jinxin Shi; Yasuo Ding; Hongxia Yin; Chunhua Hang
Journal:  Mediators Inflamm       Date:  2007       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.